Results 11 to 20 of about 7,568,653 (278)

Pathological Connections between Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease

open access: yesKidney Diseases, 2022
Background: Nonalcoholic fatty liver disease and chronic kidney disease are major public health issues worldwide. The clinical burden of nonalcoholic fatty liver disease is not only confined to liver-related morbidity and mortality, but it also includes ...
Huixia Liu, Chun Zhang, Jing Xiong
doaj   +1 more source

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease

open access: yesРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии, 2022
Aim: present clinical guidelines, aimed at general practitioners, gastroenterologists, cardiologists, endocrinologists, comprise up-to-date methods of diagnosis and treatment of non-alcoholic fatty liver disease.Key points.
V. T. Ivashkin   +22 more
doaj   +1 more source

Nonalcoholic fatty liver disease and cardiovascular disease phenotypes

open access: yesSAGE Open Medicine, 2020
Nonalcoholic fatty liver disease is increasingly recognized as a major global health problem. Intertwined with diabetes, metabolic syndrome, and obesity, nonalcoholic fatty liver disease embraces a spectrum of liver conditions spanning from steatosis to ...
Giandomenico Bisaccia   +6 more
doaj   +1 more source

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis

open access: yesHepatology, EarlyView., 2022
Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan   +22 more
wiley   +1 more source

Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver DiseaseSummary

open access: yesCellular and Molecular Gastroenterology and Hepatology, 2023
Nonalcoholic fatty liver disease (NAFLD) is a fast growing, chronic liver disease affecting ∼25% of the global population. Nonalcoholic fatty liver disease severity ranges from the less severe simple hepatic steatosis to the more advanced nonalcoholic ...
Leke Wiering   +2 more
doaj   +1 more source

A dual-responsive fluorescent probe for imaging viscosity and polarity in nonalcoholic fatty liver disease. [PDF]

open access: yesSmart Mol
We developed a BODIPY‐based fluorescent probe with dual responsiveness to viscosity and polarity, enabling sensitive and precise imaging of non‐alcoholic fatty liver disease. Abstract Viscosity and polarity are critical physiological parameters implicated in the onset and progression of nonalcoholic fatty liver disease (NAFLD).
Zhao D   +10 more
europepmc   +2 more sources

Nonalcoholic fatty liver disease [PDF]

open access: yesCanadian Medical Association Journal, 2005
Nonalcoholic fatty liver disease is emerging as the most common chronic liver condition in the Western world. It is associated with insulin resistance and frequently occurs with features of the metabolic syndrome. Disease presentation ranges from asymptomatic elevated liver enzyme levels to cirrhosis with complications of liver failure and ...
Leon A, Adams   +2 more
openaire   +3 more sources

Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice

open access: yesHepatology, EarlyView., 2022
Graphical summary of obesity‐induced NASH progression by LCN2 targeted to HSC activation. Abstract Background and Aims In obesity and type 2 diabetes mellitus, leptin promotes insulin resistance and contributes to the progression of NASH via activation of hepatic stellate cells (HSCs).
Kyung Eun Kim   +12 more
wiley   +1 more source

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses

open access: yesFrontiers in Pharmacology, 2023
Background: Resveratrol, a polyphenol found in various plants, is known for its diverse bioactivities and has been explored in relation to nonalcoholic fatty liver disease (NAFLD). However, no high-quality evidence exists regarding its efficacy.Objective:
Xuan He   +4 more
doaj   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

open access: yesHepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy